• 1. Dissociation of large gaseous serine clusters produces abundant protonated serine octamer
  Jacob S. Jordan,Evan R. Williams Analyst, 2021,146, 2617-2625
• 2. Exchanged ligands on the surface of a giant cluster: [(MoO3)176(H2O)63(CH3OH)17Hn](32 – n)–
  Chem. Commun., 1998, 1501-1502
• 3. Establishment and implications of a characterization method for magnetic nanoparticle using cell tracking velocimetry and magnetic susceptibility modified solutions
  Huading Zhang,Lee R. Moore,Maciej Zborowski,P. Stephen Williams,Shlomo Margel,Jeffrey J. Chalmers Analyst, 2005,130, 514-527
• 4. Fast-pulsing NMR techniques for the detection of weak interactions: successful natural abundance probe of hydrogen bonds in peptides?
  Amandine Altmayer-Henzien,Valérie Declerck,David J. Aitken,Ewen Lescop,Denis Merlet,Jonathan Farjon Org. Biomol. Chem., 2013,11, 7611-7615
• 5. Fate of single walled carbon nanotubes in wetland ecosystems?
  Joseph H. Bisesi,Tara Sabo-Attwood Environ. Sci.: Nano, 2014,1, 574-583

Comprehensive Overview of 1’-Hydroxy N-Trityl Medetomidine (CAS No. 176721-03-2): Properties, Applications, and Research Insights

1’-Hydroxy N-Trityl Medetomidine (CAS No. 176721-03-2) is a specialized derivative of medetomidine, a compound widely recognized for its role in pharmaceutical and biochemical research. This derivative, characterized by the addition of a trityl group and a hydroxyl moiety, exhibits unique properties that make it valuable in advanced synthetic chemistry and drug development. Researchers and industry professionals frequently search for terms like "medetomidine derivatives," "trityl-protected compounds," and "CAS 176721-03-2 applications" to explore its potential. This article delves into the molecular structure, synthesis pathways, and emerging applications of this compound, addressing common queries while aligning with current scientific trends.

The molecular structure of 1’-Hydroxy N-Trityl Medetomidine incorporates a hydroxyl group at the 1’ position and a trityl (triphenylmethyl) group attached to the nitrogen atom. This modification enhances the compound's stability and solubility, making it suitable for selective reactions in organic synthesis. Recent studies highlight its utility as a protective intermediate in the preparation of complex molecules, particularly in the development of alpha-2 adrenergic receptor agonists. Keywords such as "N-trityl protection mechanism" and "hydroxyl group reactivity" reflect growing interest in its mechanistic applications.

In the context of current research trends, 1’-Hydroxy N-Trityl Medetomidine has gained attention for its potential role in precision medicine and targeted drug delivery systems. With the rise of AI-driven drug discovery, computational models often reference this compound to predict binding affinities or optimize pharmacokinetic profiles. Searches for "medetomidine analogs in drug design" or "CAS 176721-03-2 solubility data" underscore its relevance in modern pharmacology. Additionally, its compatibility with green chemistry principles—such as reduced waste generation—aligns with sustainability goals, a hot topic in scientific communities.

From a synthetic perspective, the preparation of 1’-Hydroxy N-Trityl Medetomidine involves multi-step reactions, including selective hydroxylation and trityl group incorporation. Analytical techniques like NMR spectroscopy and high-performance liquid chromatography (HPLC) are critical for purity assessment. Researchers often inquire about "synthesis protocols for trityl derivatives" or "characterization methods for CAS 176721-03-2," emphasizing the need for standardized procedures. The compound's stability under various pH conditions also makes it a candidate for prodrug development, a trending area in pharmaceutical sciences.

Beyond laboratory applications, 1’-Hydroxy N-Trityl Medetomidine is explored for its potential in veterinary medicine, particularly in sedative formulations. However, unlike its parent compound medetomidine, this derivative requires further clinical validation. Queries like "veterinary uses of medetomidine analogs" or "safety profile of 176721-03-2" indicate user interest in translational research. Regulatory compliance and Good Manufacturing Practices (GMP) are frequently discussed in relation to its large-scale production, ensuring adherence to quality standards.

In summary, 1’-Hydroxy N-Trityl Medetomidine (CAS No. 176721-03-2) represents a versatile tool in both academic and industrial settings. Its structural features and functional groups enable diverse applications, from synthetic chemistry to therapeutic innovation. By addressing high-search-volume terms like "trityl-protected medetomidine synthesis" and "176721-03-2 research papers," this overview bridges the gap between technical expertise and user curiosity. As scientific advancements continue, this compound is poised to play a pivotal role in next-generation research.

• 33016-47-6(1-Trityl-1H-imidazole-4-carbaldehyde)
• 152146-59-3(4-(2-Butyl-5-formyl-1H-imidazol-1-yl)methylbenzoic Acid)
• 144689-24-7(Olmesartan)
• 160446-35-5(3-(N-1-Trityl-imidazol-4-yl)propionic Acid)
• 195053-89-5(3-(1-Trityl-1H-imidazol-4-yl)propan-1-amine)
• 195053-92-0(2-(1-Trityl-1H-imidazol-4-yl)-ethylamine)
• 82594-80-7(4-Methyl-1-trityl-1H-imidazole)
• 183500-36-9(Benzonitrile,4-[[5-(hydroxymethyl)-1H-imidazol-1-yl]methyl]-)
• 186096-23-1(3-(1-Tritylimidazol-4-yl) Propionaldehyde)
• 191103-80-7(1-Trityl-1H-imidazole-4-carboxylic acid)